Development of artificial lung surfactant

1.人工表面活性剂的开发A）对脂质最佳组合物的研究（1993）：在未成熟的兔子中评价了由不同比例的合成二棕榈酰磷脂酰胆碱（DPPC）、磷脂酰甘油（PG）和二油酰磷脂酰胆碱（DOPC）以及表面活性剂相关蛋白-B和-C（SP-B和SP-C）组成的几种重构表面活性剂的活性。B）对蛋白质最佳组成的研究（1994）：在未成熟的家兔中评价了由从肺分离的脂质加上不同剂量的SP-B和SP-C组成的几种重构表面活性剂的活性。含0.7% SP-B和1.4% SP-C的肺表面活性剂最能改善肺的静态压力-容量关系，但潮气量不能完全恢复正常。联合收割机结合脂质和蛋白质的方法有待进一步研究.用表面活性剂治疗成人呼吸窘迫综合征（ARDS）A）肺内滴注法（1993）。表面活性剂悬浮液的滴注（50 mg/ml，2 ml/kg）经气管注入内毒素诱导的大鼠ARDS模型（50 mg/kg）使动脉血氧分压（PaO_2）由85 mmHg提高到345 mmHg B）表面活性剂吸入给药（1994）：吸入肺表面活性物质气雾剂可使ARDS大鼠PaO_2由84 mmHg降至243 mmHg（P<0.05）。本研究结果提示，雾化吸入表面活性物质可用于临床ARDS的治疗，我们应尽快，研制出一种有效的人工表面活性剂。

1. Development of artificial surfactantA) Investigation for the best composition of lipids (1993) : Activity of several reconstituted surfactants that consisted of synthetic dipalmitoylphosphatidylcholine (DPPC) , phosphatidylglycerol (PG) and dioleoylphosphatidylcholine (DOPC) with different ratios plus surfactant-associated proteins-B and-C (SP-B and SP-C) was evaluated in immature rabbits. The surfactant composed of DPPC : PG : DOPC at a ratio of 60 : 20 : 20 showed the best activity.B) Investigation for the best composition of proteins (1994) : Activity of several reconstituted surfactants that consisted of isolated lipids from lung plus different doses of SP-B and SP-C were evaluated in immature rabbits. The surfactant containing SP-B at 0.7% and SP-C at 1.4% improved the static pressure-volume relationship of the lung at the best, but the tidal volume was not completely normalized. Further studies are necessary for method to combine lipids and proteins.2. Treatment of adult repiratory distress syndrome (ARDS) with surfactantA) Intratracheal instillation method (1993) . Instillation of surfactant suspension (50 mg/ml, 2 ml/kg) into the trachea of rats with ARDS that induced by endotoxin (50 mg/kg) improved the arterial oxygen pressure (PaO_2) from 85 mmHg to 345 mmHg (P<0.05) , but caused hypotension.B) Administration of surfactant by inhalation (1994) : Inhalation of surfactant aerosol improved the PaO_2 of ARDS rats from 84 mmHg to 243 mmHg (P<0.05) without causing hypotension.Comments and conclusionsThe present results suggest that inhalation of aerosolized surfactant can apply for treatment of clinical ARDS.We should make haste to develope an effective artificial surfactant.